-
Featured Authors
Archive
- May 2013 (1)
- April 2013 (5)
- March 2013 (2)
- February 2013 (4)
- January 2013 (1)
- December 2012 (2)
- November 2012 (3)
- October 2012 (3)
- September 2012 (3)
- August 2012 (5)
- July 2012 (4)
- June 2012 (7)
- May 2012 (5)
- April 2012 (3)
- March 2012 (4)
- February 2012 (6)
- January 2012 (2)
- December 2011 (2)
- November 2011 (3)
- October 2011 (3)
- September 2011 (5)
- August 2011 (4)
- July 2011 (8)
- June 2011 (16)
- May 2011 (8)
- April 2011 (9)
- March 2011 (14)
- February 2011 (9)
- January 2011 (15)
- December 2010 (7)
- November 2010 (6)
- October 2010 (4)
- June 2010 (1)
- May 2010 (4)
- April 2010 (14)
- March 2010 (4)
- January 2010 (5)
- November 2009 (3)
- October 2009 (1)
- August 2009 (6)
- July 2009 (9)
- June 2009 (9)
- May 2009 (8)
- April 2009 (9)
- March 2009 (9)
- February 2009 (3)
- January 2009 (1)
- November 2008 (1)
Category Archives: Patently BIOtech
Foley & Lardner article on the history of the Chinese Bayh-Dole Act
China Bayh-Dole Act: A Framework Fundamental to Achieving the Economic Potential of China’s National Patent Development Strategy (2011 – 2020) By Max Lin, Foley & Lardner LLP This article is part of our Spring 2011 edition of Legal News: China Quarterly Newsletter, Eye on China. China’s National Patent Development Strategy (2011 – 2020) (Plan) was announced in November 2010. The proposed measures focus on enhancing China’s IP system and encouraging local individuals, institutions, and companies to Read More >
Scientists oppose European stem cell patent ban
Great article about leading stem cell scientists stating that the ECJ Advocate’s recommendation to ban stem cell patents will block development of stem cell-based therapeutics in Europe. Here are the highlights from the article: Scientists oppose European stem cell patent ban By Kate Kelland, Health and Science Correspondent LONDON | Wed Apr 27, 2011 1:05pm EDT LONDON (Reuters) – Research scientists hit out on Wednesday at a European Court of Justice (ECJ) case they say could block development of embryonic Read More >
Media Coverage of BIO’s Intellectual Property Conference in Seattle
Stanford v. Roche: An Academic/Industry Collaboration Gone Wrong A Landmark Case: The Aftermath of Myriad Genetics Ethical Issues: Staying in the Frying Pan and out of the Fire
House Judiciary Committee’s Patent Reform Bill is in Need of Reform, Says BIO
PRESS RELEASE WASHINGTON, D.C. (Friday, April 15, 2011) - Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement regarding the America Invents Act, H.R. 1249, which passed the House Committee on the Judiciary yesterday: “BIO has consistently praised House Judiciary Committee Chairman Lamar Smith (R-TX) for his introduction of a comprehensive patent reform bill similar to the bill adopted by the U.S. Senate earlier this month by a nearly unanimous vote. Read More >
Fabry Patient Law Suit and Request to NIH for March-in Petition Rehearing
An article out of the Genomics Law Report discussing the recent law suit citing violations of the Bayh Dole Act. A second article from Patent Docs discusses the request for rehearing of the patients petition to the NIH for march-in.
